



Great success of ABIVAX IPO on Euronext Paris, with €57.7 million raised

Full exercise of the extension clause and of the overallotment option
Share price set at €21.30 - mid-point of the price range
Market capitalization of €205 million on a non-diluted basis

ABIVAX DEVELOPS NOVEL THERAPIES FOR LIFE-THREATENING VIRAL DISEASES

- ABIVAX's goal is to become one of the global leaders of anti-viral therapies
- Two first-in-class products with long-lasting effects in advanced clinical trials have already demonstrated safety and efficacy for chronic Hepatitis B and safety for the treatment of HIV
- A unique anti-viral platform "killing" viral RNAs
- Pioneering partnerships with Cuban biotechnology centers

Paris (France), June 23, 2015 – ABIVAX, a clinical stage biotech company specializing in the discovery, development and commercialization of anti-viral therapies, today announced the successful completion of its Initial Public Offering (IPO) on Euronext's regulated market in Paris (Euronext Paris) raising a total of €57.7 million. The Board of Directors of ABIVAX met on June 23, 2015 and decided to fully exercise the extension clause and the lead managers and bookrunners decided to exercise the overallotment option. ABIVAX will issue 2,707,089 new shares at a price of €21.30 per share. On the basis of the offer price, the company's market capitalization is €205 million on a non-diluted basis.

OFFER HIGHLIGHTS

- Global placement: €56.2 million of demand
- Public open price offering in France aimed at retail investors: €9.5 million of demand (448,134 shares)
- The final IPO price was set at €21.30 per share (mid-point of range)
- 2,707,089 new shares were issued, including full exercise of the extension clause and the overallotment option
- The market capitalization of ABIVAX is €205 million on a non-diluted basis
- Global placement: Institutional investors have been allocated 2,373,853 shares, i.e. 87.7 % of the total number of shares
- €33 million previously committed as mentioned in the prospectus and 100% allocated
- Public open price offering: Retail investors have been allocated 333,236 shares, i.e. 12.3 % of the total number of shares
- The proceeds of the IPO will be used to finance the clinical development programs for both lead products (ABX203 and ABX464) and specifically a pivotal study in Asia of ABX203 for the treatment of chronic Hepatitis B and the Phase II clinical trials of ABX464 in patients with HIV/AIDS.
- ABIVAX's shares will be listed on Euronext Paris under the ISIN code FR0012333284 and ticker ABVX. Settlement and delivery of the shares will take place on June 25, 2015. The first day of trading will be June 26, 2015.
- After the IPO, the number of shares will be 9,624,889 (10,923,489 shares on a fully diluted basis).



Professor Hartmut Ehrlich, M.D., CEO of ABIVAX, said: “We are very pleased with the success of this transaction, which is the biggest biotech IPO in France in terms of the amount raised. The success of our IPO reflects investors’ confidence in ABIVAX’s portfolio of novel antiviral treatments at an advanced development stage and in the management’s ability to execute the Company’s strategy. ABIVAX was founded to become a global leader in the treatment of severe and life-threatening viral diseases. We are pleased with the strong demand we have seen from European family offices and institutional investors, as well as from retail investors in France. Our two lead compounds ABX203 (chronic Hepatitis B) and ABX464 (HIV/AIDS), both first-in-class anti-virals, have delivered very promising results. Our ongoing clinical trials should allow us to confirm and reinforce their medical benefits.”

Dr Philippe Pouletty, M.D., Chairman and Founder of ABIVAX added: “ABIVAX is now well positioned to execute its strategy to become a leader in immuno-virology. The company will continue to develop its antiviral treatments towards commercialisation to provide care for patients with Chronic Hepatitis B, AIDS, Dengue or Chikungunya. We will continue to capitalize on the expertise of our laboratories in Montpellier and strengthen our privileged collaborations with Cuban Biotechnology institutes and CNRS.”

Upcoming events

June 25, 2015	Settlement/delivery of the OPO and the Global Placement shares
June 26, 2015	Beginning of trading of the Company’s shares on the regulated market of Euronext in Paris

Codes of the ABIVAX shares

- Company: ABIVAX
- ISIN: FR0012333284
- Ticker: ABVX
- Listing venue: Euronext Paris, Compartment B
- Sector: 4573 – Biotechnology (classification ICB)

Financial Intermediaries

Joint Lead Managers and Joint Bookrunners



RBC Capital Markets



Co-Lead Manager
Pareto Securities

AVAILABILITY OF THE PROSPECTUS

Copies of the prospectus, which received a visa from the AMF on June 4th, 2015 under number 15-255, comprising the registration document filed with the AMF on May 19, 2015 under the number I. 15-040 and the securities note (including a summary of the prospectus), may be obtained free of charge and on request at the headquarters of ABIVAX, 5 rue de la Baume, 75008 Paris, France. The document can also be viewed and downloaded on the websites of the AMF (www.amf-france.org) and of ABIVAX (www.abivax.com).

RISK FACTORS

Attention is drawn to Chapter 4 "Risk factors" of the registration document registered by the AMF, and to Chapter 2 “Risk factors related to the Offering” of the prospectus, and especially the fact that as of today, the



Company's products are currently being developed, it has no income and is not able to pay dividend.

About ABIVAX

ABIVAX is an advanced clinical development biotech company focused on becoming a global leader in the discovery, development and commercialization of anti-viral compounds and human vaccines to treat some of the world's most important infectious diseases, including HIV/AIDS and chronic Hepatitis B.

ABIVAX has 2 compounds in clinical stage research: ABX464 a novel small molecule against HIV with a number of important potential competitive advantages, and ABX203, a therapeutic vaccine candidate that could be a cure for chronic Hepatitis B. The broader ABIVAX portfolio includes additional anti-viral compounds and vaccines that may enter the clinical stage in the coming 18 months.

ABX464 has been developed using ABIVAX' anti-viral platform that allows the Company to address a broad range of viral targets involved in the production and management of viral RNA within the host cell. ABIVAX also has access to a number of cutting edge technologies including complex molecular protein/RNA-pro interactions to discover and develop proprietary breakthrough therapies to help patients' clear important pathogenic viruses.

Headquartered in Paris, France, ABIVAX conducts its research and development in Évry (France) and Montpellier (France). In addition, ABIVAX benefits from long term partnerships with the Cuban Center for Genetic Engineering and Biotechnology (Havana, Cuba), The Finlay Institute (Havana, Cuba), the Molecular Genetics Institute of Montpellier (CNRS-Université de Montpellier, France), the Curie Institute (Paris, France), the Scripps Research Institute (La Jolla, CA, USA), the University of Chicago (Chicago, IL, USA), Brigham Young University (Provo, UT, USA), and the Institut Pasteur (Paris, France). ABIVAX intends to pursue further business development opportunities to access commercial products as part of its overall corporate strategy.

ABIVAX was founded by Dr. Philippe Pouletty, M.D., managing partner at Truffle Capital, the cornerstone investor in ABIVAX since its creation.

For more information, please visit the company's website: www.ABIVAX.com

Contacts

ABIVAX

Prof. Hartmut J. Ehrlich, CEO

Press Relations

Citigate Dewe Rogerson

David Dible
david.dible@citigatedr.co.uk
+44 20 7282 2949

ALIZE RP

Caroline Carmagnol & Valentine Boivin
abivax@alizerp.com
+33 1 44 54 36 63 / + 33 6 64 18 99 59

Disclaimer

This press release must not be published, released or distributed, directly or indirectly, in the United States, Canada, Australia or Japan. This press release and the information contained herein do not constitute an offer to sell or subscribe, nor the solicitation of an order to purchase or subscribe, securities in any country other than France.

Securities may not be offered or sold in the United States unless they are registered under the U.S. Securities Act of 1933 ("U.S. Securities Act"), or are exempt from registration thereunder. The shares of ABIVAX have not been and are will not be registered under the U.S. Securities Act and ABIVAX does not intend to make a public offer of such securities in or into the United States.

The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations. Therefore, persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and comply with such laws or regulations.